Premium
Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia
Author(s) -
Denzlinger,
Bowen,
Benz,
Gelly,
Brugger,
Kanz
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.01825.x
Subject(s) - medicine , melphalan , myeloid leukaemia , myelodysplastic syndromes , myeloid , bone marrow , peripheral , gastroenterology , oncology , chemotherapy
We treated 21 elderly patients with high‐risk myelodysplasia ( n = 14) or secondary acute myeloid leukaemia ( n = 7) with 2 mg of melphalan orally once a day until a complete peripheral response was obtained or until there was evidence of treatment failure. We observed seven (30%) complete and two (10%) partial peripheral responses occurring within 4–16 weeks and lasting for 12 + to 55 weeks. In relapse, retreatment was successful in most of the patients. Responses were associated with the absence of complex cytogenetic abnormalities and with a normal or reduced bone marrow cellularity.